Adding rivaroxaban to standard care can reduce the incidence of limb, heart, and brain events in patients with PAD who have undergone a recent peripheral revascularization, according to new data ...
US regulators have approved Bayer/Janssen’s Xarelto to cut the risk of major cardiovascular (CV) events in people with chronic coronary or peripheral artery disease (CAD/PAD). US regulators have ...
Patients who have both coronary and peripheral artery disease experience consistent reductions in ischemic complications after coronary stent placement when treated with extended dual antiplatelet ...
Please provide your email address to receive an email when new articles are posted on . The Foundation to Advance Vascular Cures has launched a new virtual educational resource directed at medical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback